文献速递神经肿瘤

≥10岁弥漫性内生型脑桥胶质瘤患者的特征:国际DIPG/DMG登记报告

Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
PubMed 文献 · Neuro Oncol · 2022-01-01

该研究基于国际DIPG/DMG登记数据库,纳入208例≥10岁诊断且影像确认的DIPG患者,其中152例符合条件,中位年龄12岁。中位总生存期为13个月,1年、3年、5年OS分别为59.2%、5.3%、3.3%。长期生存者更年长且症状持续时间更长,H3变异状态不影响生存。

要点

  • ≥10岁DIPG患者中位OS为13个月,5年OS仅3.3%。
  • 长期生存者(≥24个月)更年长且症状持续时间更长。
  • H3K27M变异率77%,ATRX变异率33%,高于一般DIPG人群。

核心结论

  • ≥10岁DIPG患者中位生存期为13个月。
  • 长期生存者症状持续时间更长且诊断时年龄更大。
  • H3变异存在与否不影响生存。

研究设计与样本

  • 基于国际DIPG/DMG登记数据库的回顾性队列研究。
  • 纳入208例≥10岁且影像确认的DIPG患者,其中152例符合条件。
  • 中位年龄12岁(范围10-26.8岁)。

主要发现

  • 中位OS为13个月(范围2-82个月)。
  • 1年、3年、5年OS分别为59.2%、5.3%、3.3%。
  • 18/152例(11.8%)为长期生存者(≥24个月)。
  • 长期生存者更可能年龄更大(P < .01)且症状持续时间更长(P < .01)。
  • 50例(33%)接受活检和/或尸检;检测患者中H3K27M(H3F3A或HIST1H3B)变异率77%,TP53为61%,ATRX为33%,ACVR1为6%。

关键数值与推荐

  • 长期生存者定义为OS≥24个月,短期生存者定义为OS<24个月。
  • 18例接受IDH1检测的患者中2例为IDH1突变,其中1例为长期生存者。

临床怎么用

  • 对于≥10岁DIPG患者,应认识到其总体预后仍差,中位生存期约13个月。
  • 症状持续时间较长且年龄较大的患者可能预后相对较好,可纳入咨询考量。

局限性

  • 为登记数据库的回顾性分析,活检和/或尸检率仅33%,分子数据有限。
  • IDH1检测仅18例,相关结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can occur in adolescents and young adults. The purpose of this study was to describe clinical, radiological, pathologic, and molecular characteristics in patients ≥10 years of age with DIPG enrolled in the International DIPG Registry (IDIPGR). METHODS: Patients ≥10 years of age at diagnosis enrolled in the IDIPGR with imaging confirmed DIPG diagnosis were included. The primary outcome was overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term survivors (STS) (<24 months). RESULTS: Among 1010 patients, 208 (21%) were ≥10 years of age at diagnosis; 152 were eligible with a median age of 12 years (range 10-26.8). Median OS was 13 (2-82) months. The 1-, 3-, and 5-year OS was 59.2%, 5.3%, and 3.3%, respectively. The 18/152 (11.8%) LTS were more likely to be older (P < .01) and present with longer symptom duration (P < .01). Biopsy and/or autopsy were performed in 50 (33%) patients; 77%, 61%, 33%, and 6% of patients tested had H3K27M (H3F3A or HIST1H3B), TP53, ATRX, and ACVR1 mutations/genome alterations, respectively. Two of 18 patients with IDH1 testing were IDH1-mutant and 1 was a LTS. The presence or absence of H3 alterations did not affect survival. CONCLUSION: Patients ≥10 years old with DIPG have a median survival of 13 months. LTS present with longer symptom duration and are likely to be older at presentation compared to STS. ATRX mutation rates were higher in this population than the general DIPG population.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Erker C, Lane A, Chaney B, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022. PMID: 34114629. doi:10.1093/neuonc/noab140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。